Atea Pharmaceuticals Inc

NASDAQ:AVIR  
6.45
-0.47 (-6.79%)
Products, Regulatory

Atea Pharmaceuticals Highlights Strategic Priorities For 2022

Published: 01/07/2022 12:32 GMT
Atea Pharmaceuticals Inc (AVIR) - Atea Pharmaceuticals Highlights Strategic Priorities for 2022.
Atea Pharmaceuticals Inc - Planning Global Phase 2 Outpatient Trial for Bemnifosbuvir (at-527) Designed to Support Anticipated Combination Trials.
Atea Pharmaceuticals Inc - Atea is Advancing At-752 to a Phase 2 Proof-of-concept Program for Treatment of Dengue Fever.